v3.25.2
Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2025
Accounting Policies [Abstract]  
Schedules of Concentration of Risk, by Risk Factor
A significant customer is any biopharmaceutical customer, clinical testing payer, or international laboratory partner that represents 10% or more of the Company’s total revenue or accounts receivable balance. Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company’s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company’s total accounts receivable balance, at the respective condensed consolidated balance sheet date, are as follows:
Revenue
Accounts Receivable, Net
Three Months Ended June 30,Six Months Ended June 30,June 30,
2025		December 31,
2024
2025202420252024
(unaudited)(unaudited)
Customer A
*12 %**14 %14 %
Customer B
28 %29 %28 %30 %10 %12 %
Customer C
****13 %11 %
*    less than 10%
Schedule of Disaggregation of Revenue
The following table presents the Company’s revenue disaggregated by revenue source:
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
(unaudited)
(in thousands)
Oncology$158,685 $130,269 $309,244 $256,017 
Biopharma and data
56,020 43,933 101,396 81,520 
Screening14,814 — 20,491 — 
Licensing and other
2,569 3,033 4,428 8,189 
Total revenue
$232,088 $177,235 $435,559 $345,726